The Effects of Allopurinol on Redox Sensitive Transcription Factors, Pro- Inflammatory Cytokines and Heme Oxygenase-1 in Acetic Acid-Induced Colitis in Rats

Total Page:16

File Type:pdf, Size:1020Kb

The Effects of Allopurinol on Redox Sensitive Transcription Factors, Pro- Inflammatory Cytokines and Heme Oxygenase-1 in Acetic Acid-Induced Colitis in Rats Acta Medica Mediterranea, 2018, 34: 119 THE EFFECTS OF ALLOPURINOL ON REDOX SENSITIVE TRANSCRIPTION FACTORS, PRO- INFLAMMATORY CYTOKINES AND HEME OXYGENASE-1 IN ACETIC ACID-INDUCED COLITIS IN RATS ULVI DEMIREL1, MEHMET YALNIZ1, CEMAL ORHAN2, NURETTIN TUNC1, ABDURRAHMAN SAHIN1, MEHMET TUZCU3, KAZIM SAHIN2, IBRAHIM HANIFI OZERCAN4, IBRAHIM HALIL BAHÇECIOGLU1 1Department of Gastroenterology, School of Medicine, Firat University, Elazig, Turkey - 2Department of Animal Nutrition, Faculty of Veterinary Science, Firat University, Elazig, Turkey - 3Department of Biology, Faculty of Science, Fırat University, Elazig, Turkey - 4Department of Pathology, School of Medicine, Firat University, Elazig, Turkey ABSTRACT Introduction: Oxidative stress plays an important role in pathophysiology of inflammatory bowel diseases. We aimed to inve- stigate the effects of antioxidant allopurinol (AP) and the potential mechanisms leading amelioration upon acetic acid induced coli- tis. Materials and methods: Twenty-eight rats were divided in four groups. Control rats received 1 mL of NaCl (0.9%). In the AA group rats received 1 mL of 5% (v/v) acetic acid. The rats in the AAAP group received 1 mL of 5% (v/v) acetic acid. Additionally these rats received 100 mg/kg AP. AP group rats received only 100 mg/kg AP. Histopathological, biochemical and western blot analy- sis were done. Results: In the AA group, colonic injury scores, malondialdehyde (MDA), NF-κB p65, TNFα, COX2, AP-1 and IL-6 levels were significantly higher than in the control group (P<0.05). In the AAAP treatment group the colonic injury scores, MDA, NF-κB p65, TNFα, COX2, AP-1 and IL-6 levels significantly decreased when compared to the AA treated rats (P<0.05). The expression of HO-1 in the AAAP group significantly increased when compared to the AA treated rats (P<0.05). Conclusion: Intra colonic acetic acid instillation causes severe intestinal injury accompanied to increased oxidative stress. AP treatment ameliorates this injury by overcoming oxidative stress and regulating cellular redox balance in favor of antioxidant defense mechanisms probably via manipulation of redox sensitive transcription factors. Keywords: Oxidative Stress, Allopurinol, Acetic Acid, Colitis, Redox Sensitive Transcription Factors. DOI: 10.19193/0393-6384_2018_1_20 Received November 30, 2017; Accepted January 20, 2018 Introduction pathways for excessive reactive oxygen species (ROS) generation, and this enzyme is present at the Ulcerative colitis (UC) and Crohn's disease highest level in the intestine. XO-derived ROS (CD) are chronic and idiopathic intestinal inflam- causes tissue injury in various ways such as direct matory disorders. Although the pathophysiology of damaging cellular components, activation of these disorders is not completely understood, accu- nuclear factor-kappa B (NF-қB) signaling pathway, mulated experimental and clinical data suggests and upregulation of inducible nitric oxide synthase that increased oxidative stress plays important role (iNOS)(2, 3). Allopurinol (AP) is a competitive in these diseases initiation and progression(1). inhibitor of XO enzyme and has dose dependent Xanthine oxidase (XO) enzyme is one of the major free radical scavenging ability(4). 120 Ulvi Demirel, Mehmet Yalniz et Al Additionally, AP decreases tumor necrosis fac- deprived of not water for 24 h prior to the induction tor-alpha (TNF-α) and the expression of intercellu- of chemical colitis. The study protocol was in lar adhesion molecules-1 (ICAM-1) production. It accordance with the guidelines for animal research has been also reported that AP can down-regulate and approved by the Ethics Committee of Firat ROS dependent activation of NF-қB which is a University Medical Faculty. very important mediator of tissue inflammation. Useful effects of XO inhibition have been reported Experimental Design and Induction of with AP and amflutizole treatment in different coli- Colitis tis models(5-7). Twenty eight rats were divided four group: Heme oxygenase-1 (HO-1) is considered as a Control group (C), acetic acid group (AA), acetic major cellular defense system against oxidative acid+100 mg/kg allopurinol (AAAP) group, and insults. In increased oxidative stress conditions HO- only 100 mg/kg allopurinol (AP) group. Each group 1 production is upregulated by redox sensitive tran- consisted of seven rats. Fasted animals were lightly scription factors, including NF-қB, activator pro- anesthetized with ether. Control rats received 1 mL tein-1 (AP-1), and nuclear factor E2-related factor- of NaCl (0.9%) by intracolonic with a flexible plas- 2 (Nrf2)(8). Cyclooxygenase-2 (COX-2) is also tic rubber catheter with an outside diameter of 2 induced mainly at sites of inflammation by above mm which was inserted 8 cm into the colon via the factors like HO-1 enzyme. It has been demonstrated anus. In the AA group rats received 1 mL of 5% that intestinal inflammation can be prevented by (v/v) acetic acid in 0.9% NaCl by intracolonic with inhibition of COX-2 expression(9). At the present the same tip of cannula in the control group (10). day, it is well known that synthesis pro-inflammato- The rats in the AAAP group were subjected to the ry mediators and antioxidant defense enzymes are same procedure in the AA group rats. Additionally, strictly controlled at the nuclear level by aforemen- these rats received 100 mg/kg AP (Ürikoliz® 300 tioned redox-sensitive transcription factors. mg tablet, obtained from Sandoz, Turkey) by Therefore, development of the new treatments tar- intraperitoneal (ip) route at the same day of the col- geting the manipulation of these redox sensitive itis induction and AP treatment was continued for signaling is considered as ideal strategies to prevent seven consecutive days. To avoid chemical, infec- or treat oxidative stress-related diseases. tious peritonitis and achieve optimal dissolution, In contrast to drugs that have been already the AP was dissolved in sterile water and then titrat- used in inflammatory bowel diseases (IBD) treat- ed to pH 11 with NaOH under strict sterile condi- ment including 5-ASA, corticosteroids and biologi- tions(7). cal agents, allopurinol is cheap, and has been gener- Allopurinol treatment solutions were prepared ally regarded as a safe drug. All these data about AP and used daily. In the AP group rats were subjected suggest that AP may be a considerably proper can- to the same procedure in the control group rats. didate for prevention of intestinal inflammation. In Additionally, in this group rats received AP treat- this study we aimed to investigate the effects of AP ment at the same dose, route and duration in the treatment on redox sensitive transcription factors AAAP group rats. At the end of the seventh day all (AP-1, NF-қB, Nrf2, and TNF-α) and these factors rats were decapitated. The colon was removed at mediated synthesis of pro-inflammatory COX-2 the level of 8 cm from the anus. The colon were interleukin-6 (IL-6) and antioxidant HO-1 enzyme opened longitudinally, and rinsed with saline solu- in acetic acid-induced colitis in rats. tion. Then, colon samples were cut in two parts. One part fixed in 10% neutral buffered formalin for Material and methods histopathological examination. Other tissue samples were stored at -70°C for subsequent measurement Animals of tissue malondialdehyde (MDA), NF-қB, AP-1, Healthy, male, Albino, Wistar strain rats, Nrf2, and TNF-α, HO-1, COX2 and IL-6 levels. weighing 250-300g, were purchased from the Firat University Laboratory Animal Research Center Histopathological Examination of Colon (Elazig, Turkey). The animals were housed at tem- Distal colon segments which were fixed in perature-controlled (24±1 °С), humidity of 55 ±5%, 10% phosphate-buffered formaldehyde, embedded alternating 12 h light/12 h dark cycles, with normal in paraffin blocks and sliced in 5 µm thickness sec- rat chow and fresh water ad libitum. Rats were tions. These sections were stained with hematoxylin The effects of allopurinol on redox sensitive transcription factors, pro-inflammatory cytokines... 121 and eosin for light microscopic examination. The was added to the supernatant. Equal amounts of tissue slices were scanned and scored by two expert protein (50 μg) were electrophoresed and subse- pathologists who were unaware of sample assign- quently transferred to nitrocellulose membrane ment to the experimental groups. Histological scor- (Schleicher and Schuell Inc., Keene, NH, USA). ing was determined by examining each specimen Blots on nitrocellulose membrane were washed for following features of damage: submucosal twice for 5 min each in PBS and blocked with 1% edema, vasodilation, inflammatory cell infiltration bovine serum albumin in PBS for 1 h prior to appli- and necrosis. The degree of intestinal injury was cation of the primary antibody. The antibody scored to above features using a scale of 0-3 (nor- against Nrf-2, TNFα, COX2, AP-1, and IL-6 was mal: 0, mild: 1, moderate: 2, severe: 3) like previ- the purchased from Santa Cruz Biotechnology, Inc. ously described(11). (Santa Cruz, CA, USA). Antibodies against HO-1 and NF-κB p65 were purchased from Abcam Determination of Colonic Malondialdehyde (Cambridge, UK). Primary antibody was diluted Levels (1:1000) in the same buffer containing 0.05% The colonic samples (100 mg) were homoge- Tween-20. The nitrocellulose membrane was incu- nized in 1 mL of 0.05M Trizma base buffer (pH bated overnight at 4 °C with protein antibody. The 7.4). The homogenates were centrifuged (16,000g, blots were washed and incubated with horseradish 4 ºC) for 30 min. The supernatant was collected and peroxidase-conjugated goat anti-mouse IgG stored at -80 ºC. The colonic MDA level was mea- (Abcam, Cambridge, UK). Specific binding was sured using the fully automatic High Performance detected using diaminobenzidine and H2O2 as sub- Liquid Chromatography (HPLC) (Shimadzu, strates. Protein loading was controlled using a mon- Kyoto, Japan) equipped with a pump (LC-20AD), oclonal mouse antibody against β-actin antibody an ultraviolet-visible detector (SPD-20A), an inert- (A5316; Sigma).
Recommended publications
  • Drug Antioxidant Effects a Basis for Drug Selection?
    REVIEW ARTI LE Drugs 42 (4): 569-605, 1991 00 12-6667/ 91/ 00 I0-0569/ $ 18.50/0 © Adis International Limited. All rights reserved. DRU161 Drug Antioxidant Effects A Basis for Drug Selection? Barry Halliwell Pulmonary Medicine, UC Davis Medical Center, Sacramento , California, USA Contents 570 Summary 570 I. What is a Free Radical? 570 1.1 Definition of a Free Radical 57/ 1.2 Hydroxyl Radical 572 1.3 Formation of Oxygen Radicals In Vivo 574 1.4 Reactive Oxygen Species 575 1.5 Transition Metal Ions and Free Radical Reactions 575 1.6 Antioxidant Defence In Vivo: Intracellular 576 1.7 Antioxidant Defence In Vivo: Extracellular 579 2. Free Radical Damage to Cells and the Protective Ability of Antioxidants 579 2.1 Mechanisms of Cell Damage: The Molecular Targets 58/ 2.2 How to Characterise an Antioxidant 5 2 3. The Role of Free Radicals in Human Disease 582 3.1 Causation of Disease 582 3.2 A Significant Consequence of Disease Pathology 584 3.3 A General Consequence of Tissue Injury 585 3.4 What Can We Expect from Antioxidant Therapy? 586 586 4. Antioxidants in Disease Therapy 586 4.1 Use of Naturally Occurring Antioxidants and Derived Compounds 587 4.1.1 Superoxide Dismutase 587 4.1.2 Superoxide Dismutase 'Mimics' 588 4.1.3 a-Tocopherol 589 4.1.4 Ascorbic Acid (Vitamin C) 589 4.1.5 Adenosine 589 4.1.6 Lactoferrin 590 4.1.7 Nicotinamide 59/ 4.1.8 Glutathione and its Precursors 59/ 4.1.9 Carotenoids 59/ 4.2 'Synthetic' Antioxidants 59/ 4.2.1 Mercaptopropionylglycine and Other Thiols 592 4.2.2 Ebselen: A Glutathione Peroxidase Mimic? 593 4.2.3 Allopurinol, Oxypurinol and Other Xanth ine Oxidase Inhibitors 593 4.2.4 Inhibitors of the Generation of Reactive Oxygen Species by Phagocytes 595 4.2.5 Chelating Agents: Deferoxamine 595 4.2.6 Other Iron Chelators: Hydroxypyridones 596 4.2.7 Other Iron Chelators: ICRF-187 and the 'Lazaroids' 4.2.8 Probucol and Other Chain-Breaking Antioxidants 570 Drugs 42 (4) 1991 596 5.
    [Show full text]
  • Review Article
    Free Radical Biology & Medicine, Vol. 33, No. 6, pp. 774–797, 2002 Copyright © 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0891-5849/02/$–see front matter PII S0891-5849(02)00956-5 Review Article STRUCTURE AND FUNCTION OF XANTHINE OXIDOREDUCTASE: WHERE ARE WE NOW? ROGER HARRISON Department of Biology and Biochemistry, University of Bath, Bath, UK (Received 11 February 2002; Accepted 16 May 2002) Abstract—Xanthine oxidoreductase (XOR) is a complex molybdoflavoenzyme, present in milk and many other tissues, which has been studied for over 100 years. While it is generally recognized as a key enzyme in purine catabolism, its structural complexity and specialized tissue distribution suggest other functions that have never been fully identified. The publication, just over 20 years ago, of a hypothesis implicating XOR in ischemia-reperfusion injury focused research attention on the enzyme and its ability to generate reactive oxygen species (ROS). Since that time a great deal more information has been obtained concerning the tissue distribution, structure, and enzymology of XOR, particularly the human enzyme. XOR is subject to both pre- and post-translational control by a range of mechanisms in response to hormones, cytokines, and oxygen tension. Of special interest has been the finding that XOR can catalyze the reduction of nitrates and nitrites to nitric oxide (NO), acting as a source of both NO and peroxynitrite. The concept of a widely distributed and highly regulated enzyme capable of generating both ROS and NO is intriguing in both physiological and pathological contexts. The details of these recent findings, their pathophysiological implications, and the requirements for future research are addressed in this review.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al
    USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]